ClinicalTrials.gg
CompletedNCT03693170ANCHOR-CRCUpdated Jul 16, 2026Results posted

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

A Phase 2 interventional study of encorafenib and Binimetinib in BRAF V600E-mutant Metastatic Colorectal Cancer, sponsored by Pierre Fabre Medicament. Completed at 45 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing encorafenib in Colorectal Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. encorafenib · Colorectal Neoplasms.

Enrollment
8th of 16
95 · median 95
Started
2019
with 1 other
Phase 2
9 of 16
4 open now
Registered
5th of 16
by date
Lead sponsor
2 of 16
Pierre Fabre Medicament

Among the 16 studies testing encorafenib in Colorectal Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 5th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 16 studies testing encorafenib in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About encorafenib

encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing encorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.

Read the detailed description

The presence of a BRAFV600E mutation is considered a marker of poor prognosis in subjects with mCRC. The preclinical results and preliminary clinical data together justify the evaluation of this triple combination in the first-line setting of this population. The primary objective of the study is to evaluate the antitumor activity of the combination of encorafenib, binimetinib and cetuximab by assessing the overall response rate in adult subjects with previously untreated BRAFV600E-mutant metastatic colorectal cancer. It will also assess the effect of the triple combination on the duration of response, time to response, progression-free survival and overall survival and assess the effect on quality of life. It will also characterize the safety and tolerability of the triple combination as well as describe the pharmacokinetics (PK) of encorafenib, binimetinib, and cetuximab.

03

Conditions studied

  • BRAF V600E-mutant Metastatic Colorectal Cancer

Keywords

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 years of age
  • or cytologically confirmed CRC that is
  • Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to screening
  • Evidence of as per , v1.1
  • Subject able to receive cetuximab as per approved label with regards to RAS status
  • Status (ECOG) 0 or 1
  • Adequate renal, hepatic, cardiac and bone marrow functions and adequate electrolytes as per protocol
  • Subject able to take oral medications

Exclusion criteria

Exclusion Criteria:

  • Prior systemic therapy for disease
  • Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti-EGFR inhibitors
  • Symptomatic or
  • History or current evidence of Retinal Vein Occlusion (RVO) or current risk factors for RVO
  • History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or medications or surgery) ≤ 12 months prior to first dose.
  • Impaired cardiovascular function or cardiovascular diseases: history of myocardial infarction or coronary disorders within 6 months prior to start of study treatment, symptomatic congestive heart failure (grade 2 or higher), past or current clinically significant arrhythmia and/or conduction disorder within 6 months prior to study treatment start
  • History of thromboembolic or cerebrovascular events within 6 months prior to start of study treatment
  • Concurrent neuromuscular disorder that is associated with potential elevation of Creatine Kinase
  • Known to cetuximab administration as per SPC/approved label
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    1 Arm

    encorafenib plus binimetinib plus cetuximab

    Drug: encorafenib · Drug: Binimetinib · Drug: Cetuximab

Interventions

  • 300 mg administered orally once daily (QD)

    Also known as: Braftovi

  • Binimetinib 45 mg administered orally twice daily (BID)

    Also known as: Mektovi

  • Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) : (\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward. Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic.

    Also known as: Erbitux

06

What researchers measure

Primary outcomes

  1. Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments

    The confirmed overall response rate (cORR) is the percentage of confirmed responses, defined as complete response (CR) or partial response (PR), as assessed by local radiologist/investigator review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.

    Time frame: From initiation of treatment to disease progression up to a maximum of 17.6 months.

Secondary outcomes

  1. Confirmed Overall Response Rate (cORR) Based on Central Tumor Assessment

    The confirmed overall response rate (cORR) is the percentage of confirmed responses, defined as complete response (CR) or partial response (PR), as assessed by central radiologist review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.

    Time frame: From initiation of treatment to disease progression up to a maximum of 17.6 months

  2. Overall Response Rate (ORR) Based on Local Tumor Assessments

    The overall response rate (ORR) is the percentage of responses, defined as complete response (CR) or partial response (PR), as assessed by local radiologist/investigator review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.

    Time frame: From initiation of treatment to disease progression up to a maximum of 17.6 months

  3. Overall Response Rate (ORR) Based on Central Tumor Assessments

    The overall response rate (ORR) is the percentage of responses, defined as complete response (CR) or partial response (PR), as assessed by central radiologist review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.

    Time frame: From initiation of treatment to disease progression up to a maximum of 17.6 months

  4. Duration of Response (DOR) Per Local Assessment

    Time from first radiographic evidence of response based on local radiologist/investigator review to the earliest documented PD or death due to underlying disease

    Time frame: From first radiographic evidence of response to disease progression up to a maximum of 17.6 months

  5. Duration of Response (DOR) Per Central Assessment

    Time from first radiographic evidence of response based on central review to the earliest documented PD or death due to underlying disease

    Time frame: From first radiographic evidence of response to disease progression up to a maximum of 17.6 months

  6. Time to Response (TTR) Per Local Review

    The TTR is defined as the time from the first dose until the first documented radiographic evidence of response of CR or PR per local review

    Time frame: From initiation of treatment to the first radiographic evidence of response up to a maximum of 17.6 months

  7. Time to Response (TTR) Per Central Review

    The TTR is defined as the time from the first dose until the first documented radiographic evidence of response of CR or PR per central review

    Time frame: From initiation of treatment to the first radiographic evidence of response up to a maximum of 17.6 months

  8. Progression-Free Survival (PFS) Per Local Review

    Time from first dose to the earliest documented date of disease progression based on local radiologist/investigator review or death due to any cause

    Time frame: From initiation of treatment to disease progression or death up to a maximum of 17.6 months

  9. Progression of Free Survival (PFS) Per Central Review

    Time from first dose to the earliest documented date of disease progression based on central review or death due to any cause

    Time frame: From initiation of treatment to disease progression or death up to a maximum of 17.6 months

  10. Overall Survival (OS)

    Time from first dose to death due to any cause

    Time frame: From initiation of treatment to death up to a maximum of 17.6 months

  11. Change From Baseline in EORTC QLQ-C30 Over Time

    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for cancer subjects (EORTC QLQ-C30) includes a global health status/QoL. The scale ranges in score from 0 to 100, higher score on the global health status/QoL scale indicate higher QoL. Changes from baseline in EORTC QLQ-C30 global health status/quality of life (QoL) over time are presented in this record.

    Time frame: From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months

  12. Change From Baseline in EQ-5D-5L Over Time

    The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L VAS records the patient's self-rated health on a vertical visual analogue scale numbered from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine"). Changes from baseline in EQ-5D-5L VAS over time are presented in this record.

    Time frame: From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months

  13. PGIC Scores Over Time

    The Patient Global Impression of Change (PGIC) is a measure of patients' perceptions of change in their symptoms over time. For this assessment, subjects answered the following question: "Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse."

    Time frame: From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months

07

Results

Posted Aug 30, 2022
Limitations and caveats
The absence of a comparator arm should be noted as a limitation. In addition, the short duration of the follow-up at the data cut-off date does not allow a robust estimate of OS results.

Participant flow

95 subjects were enrolled in the study between 17 January 2019 and 27 December 2019 in 68 investigational centers : 45 in EU, 7 in UK, 10 in USA and 6 in Japan

Participant flow — Overall Study
MilestoneEncorafenib Plus Binimetinib Plus Cetuximab
Started95
Completed20
Not completed75
Withdrew: Disease progression48
Withdrew: Adverse event16
Withdrew: Physician decision6
Withdrew: Protocol violation2
Withdrew: Death1
Withdrew: Non compliance with study drug1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryConfirmed Overall Response Rate (cORR) Based on Local Tumor Assessments

The confirmed overall response rate (cORR) is the percentage of confirmed responses, defined as complete response (CR) or partial response (PR), as assessed by local radiologist/investigator review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.

Time frame:
From initiation of treatment to disease progression up to a maximum of 17.6 months.
Reported as:
Number · percentage of confirmed responses
Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments
percentage of confirmed responses1 Arm
Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments47.8 (37.3 to 58.5)
Statistical analysis
  • 1 Arm ·
SecondaryConfirmed Overall Response Rate (cORR) Based on Central Tumor Assessment

The confirmed overall response rate (cORR) is the percentage of confirmed responses, defined as complete response (CR) or partial response (PR), as assessed by central radiologist review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.

Time frame:
From initiation of treatment to disease progression up to a maximum of 17.6 months
Reported as:
Number · percentage of confirmed responses
Confirmed Overall Response Rate (cORR) Based on Central Tumor Assessment
percentage of confirmed responses1 Arm
Confirmed Overall Response Rate (cORR) Based on Central Tumor Assessment45.7 (35.2 to 56.4)
SecondaryOverall Response Rate (ORR) Based on Local Tumor Assessments

The overall response rate (ORR) is the percentage of responses, defined as complete response (CR) or partial response (PR), as assessed by local radiologist/investigator review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.

Time frame:
From initiation of treatment to disease progression up to a maximum of 17.6 months
Reported as:
Number · percentage of responses
Overall Response Rate (ORR) Based on Local Tumor Assessments
percentage of responses1 Arm
Overall Response Rate (ORR) Based on Local Tumor Assessments62 (51.2 to 71.9)
SecondaryOverall Response Rate (ORR) Based on Central Tumor Assessments

The overall response rate (ORR) is the percentage of responses, defined as complete response (CR) or partial response (PR), as assessed by central radiologist review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.

Time frame:
From initiation of treatment to disease progression up to a maximum of 17.6 months
Reported as:
Number · percentage of responses
Overall Response Rate (ORR) Based on Central Tumor Assessments
percentage of responses1 Arm
Overall Response Rate (ORR) Based on Central Tumor Assessments60.9 (50.1 to 70.9)
SecondaryDuration of Response (DOR) Per Local Assessment

Time from first radiographic evidence of response based on local radiologist/investigator review to the earliest documented PD or death due to underlying disease

Time frame:
From first radiographic evidence of response to disease progression up to a maximum of 17.6 months
Reported as:
Median · months
Duration of Response (DOR) Per Local Assessment
months1 Arm
Duration of Response (DOR) Per Local Assessment5.1 (3.7 to 6.9)
SecondaryDuration of Response (DOR) Per Central Assessment

Time from first radiographic evidence of response based on central review to the earliest documented PD or death due to underlying disease

Time frame:
From first radiographic evidence of response to disease progression up to a maximum of 17.6 months
Reported as:
Median · months
Duration of Response (DOR) Per Central Assessment
months1 Arm
Duration of Response (DOR) Per Central Assessment5.1 (3.4 to 5.5)
SecondaryTime to Response (TTR) Per Local Review

The TTR is defined as the time from the first dose until the first documented radiographic evidence of response of CR or PR per local review

Time frame:
From initiation of treatment to the first radiographic evidence of response up to a maximum of 17.6 months
Reported as:
Median · months
Time to Response (TTR) Per Local Review
months1 Arm
Time to Response (TTR) Per Local Review1.4 (1.4 to 1.5)
SecondaryTime to Response (TTR) Per Central Review

The TTR is defined as the time from the first dose until the first documented radiographic evidence of response of CR or PR per central review

Time frame:
From initiation of treatment to the first radiographic evidence of response up to a maximum of 17.6 months
Reported as:
Median · months
Time to Response (TTR) Per Central Review
months1 Arm
Time to Response (TTR) Per Central Review1.4 (1.3 to 1.4)
SecondaryProgression-Free Survival (PFS) Per Local Review

Time from first dose to the earliest documented date of disease progression based on local radiologist/investigator review or death due to any cause

Time frame:
From initiation of treatment to disease progression or death up to a maximum of 17.6 months
Reported as:
Median · months
Progression-Free Survival (PFS) Per Local Review
months1 Arm
Progression-Free Survival (PFS) Per Local Review5.8 (4.6 to 6.4)
SecondaryProgression of Free Survival (PFS) Per Central Review

Time from first dose to the earliest documented date of disease progression based on central review or death due to any cause

Time frame:
From initiation of treatment to disease progression or death up to a maximum of 17.6 months
Reported as:
Median · months
Progression of Free Survival (PFS) Per Central Review
months1 Arm
Progression of Free Survival (PFS) Per Central Review5.0 (4.6 to 6.4)
SecondaryOverall Survival (OS)

Time from first dose to death due to any cause

Time frame:
From initiation of treatment to death up to a maximum of 17.6 months
Reported as:
Median · months
Overall Survival (OS)
months1 Arm
Overall Survival (OS)17.2 (14.1 to NA)
SecondaryChange From Baseline in EORTC QLQ-C30 Over Time

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for cancer subjects (EORTC QLQ-C30) includes a global health status/QoL. The scale ranges in score from 0 to 100, higher score on the global health status/QoL scale indicate higher QoL. Changes from baseline in EORTC QLQ-C30 global health status/quality of life (QoL) over time are presented in this record.

Time frame:
From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months
Reported as:
Mean · units on a scale
Change From Baseline in EORTC QLQ-C30 Over Time
units on a scale1 Arm
C2D1-2.64 ± 19.270
C3D1-0.35 ± 20.866
C4D10.97 ± 20.238
C5D1-0.89 ± 18.026
C6D1-1.92 ± 22.544
C7D1-5.39 ± 22.834
C8D1-4.63 ± 21.225
C9D1-1.85 ± 15.274
C10D1-7.69 ± 17.167
30 days safety Follow up-15.42 ± 25.775
SecondaryChange From Baseline in EQ-5D-5L Over Time

The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L VAS records the patient's self-rated health on a vertical visual analogue scale numbered from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine"). Changes from baseline in EQ-5D-5L VAS over time are presented in this record.

Time frame:
From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D-5L Over Time
units on a scale1 Arm
C2D10.04 ± 19.707
C3D10.35 ± 21.668
C4D12.66 ± 19.400
C5D13.73 ± 17.052
C6D11.69 ± 18.421
C7D11.31 ± 18.903
C8D12.89 ± 15.882
C9D1-2.32 ± 21.945
C10D1-4.00 ± 12.503
30 days safety Follow up-9.35 ± 23.585
SecondaryPGIC Scores Over Time

The Patient Global Impression of Change (PGIC) is a measure of patients' perceptions of change in their symptoms over time. For this assessment, subjects answered the following question: "Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse."

Time frame:
From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months
Reported as:
Count of participants · Participants
PGIC Scores Over Time
Participants1 Arm
C2D1 — Very much improved5
C2D1 — Much improved15
C2D1 — Minimally improved17
C2D1 — No change29
C2D1 — Minimally worse3
C2D1 — Much worse0
C2D1 — Very much worse0
C2D1 — Missing, not done22
C3D1 — Very much improved10
C3D1 — Much improved28
C3D1 — Minimally improved11
C3D1 — No change20
C3D1 — Minimally worse0
C3D1 — Much worse0
C3D1 — Very much worse0
C3D1 — Missing, not done12
C4D1 — Very much improved9
C4D1 — Much improved31
C4D1 — Minimally improved12
C4D1 — No change16
C4D1 — Minimally worse0
C4D1 — Much worse0
C4D1 — Very much worse0
C4D1 — Missing, not done9
C5D1 — Very much improved10
C5D1 — Much improved19
C5D1 — Minimally improved11
C5D1 — No change13
C5D1 — Minimally worse2
C5D1 — Much worse0
C5D1 — Very much worse0
C5D1 — Missing, not done10
C6D1 — Very much improved7
C6D1 — Much improved18
C6D1 — Minimally improved13
C6D1 — No change13
C6D1 — Minimally worse0
C6D1 — Much worse0
C6D1 — Very much worse0
C6D1 — Missing, not done6
C7D1 — Very much improved4
C7D1 — Much improved13
C7D1 — Minimally improved7
C7D1 — No change11
C7D1 — Minimally worse0
C7D1 — Much worse0
C7D1 — Very much worse0
C7D1 — Missing, not done8
C8D1 — Very much improved4
C8D1 — Much improved11
C8D1 — Minimally improved5
C8D1 — No change5
C8D1 — Minimally worse2
C8D1 — Much worse0
C8D1 — Very much worse0
C8D1 — Missing, not done6
C9D1 — Very much improved1
C9D1 — Much improved9
C9D1 — Minimally improved2
C9D1 — No change5
C9D1 — Minimally worse0
C9D1 — Much worse0
C9D1 — Very much worse0
C9D1 — Missing, not done3
C10D1 — Very much improved2
C10D1 — Much improved4
C10D1 — Minimally improved4
C10D1 — No change4
C10D1 — Minimally worse0
C10D1 — Much worse0
C10D1 — Very much worse0
C10D1 — Missing, not done0
30 days safety Follow-up — Very much improved3
30 days safety Follow-up — Much improved12
30 days safety Follow-up — Minimally improved5
30 days safety Follow-up — No change9
30 days safety Follow-up — Minimally worse6
30 days safety Follow-up — Much worse6
30 days safety Follow-up — Very much worse0
30 days safety Follow-up — Missing, not done31

Adverse events

Collected over From patient enrolment date to 30 days after the last dose of study drug up to a maximum of 17.6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 Arm27/95 (28.4%)49/95 (51.6%)93/95 (97.9%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
Event1 Arm
Large intestinal obstructionGastrointestinal disorders6/95
Acute kidney injuryRenal and urinary disorders6/95
Intestinal obstructionGastrointestinal disorders5/95
NauseaGastrointestinal disorders5/95
Abdominal painGastrointestinal disorders4/95
DiarrhoeaGastrointestinal disorders4/95
Small intestinal obstructionGastrointestinal disorders4/95
VomitingGastrointestinal disorders4/95
AnaemiaBlood and lymphatic system disorders2/95
PyrexiaGeneral disorders and administration site conditions2/95
Most frequent other events
Showing 10 of 45
Most frequent other events
Event1 Arm
DiarrhoeaGastrointestinal disorders64/95
NauseaGastrointestinal disorders42/95
Dermatitis acneiformSkin and subcutaneous tissue disorders38/95
RashSkin and subcutaneous tissue disorders38/95
VomitingGastrointestinal disorders34/95
Abdominal painGastrointestinal disorders31/95
AstheniaGeneral disorders and administration site conditions30/95
Dry skinSkin and subcutaneous tissue disorders30/95
ConstipationGastrointestinal disorders25/95
AnaemiaBlood and lymphatic system disorders23/95

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)1 Arm
<=18 years0
Between 18 and 65 years43
>=65 years52
Age, Continuous
Age, Continuous(years)1 Arm
Median65 (57 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)1 Arm
Female51
Male44
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1 Arm
Hispanic or Latino8
Not Hispanic or Latino73
Unknown or Not Reported14
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 Arm
American Indian or Alaska Native0
Asian11
Native Hawaiian or Other Pacific Islander0
Black or African American0
White71
More than one race0
Unknown or Not Reported13
Region of Enrollment
Region of Enrollment(Participants)1 Arm
Austria1
Netherlands1
Belgium9
United States3
Japan11
Italy15
United Kingdom13
France13
Spain29
Primary tumor location
Primary tumor location(Participants)1 Arm
Right-sided/transverse57
Left-sided/rectum37
Other1
Number of metastatic organs
Number of metastatic organs(Participants)1 Arm
123
233
>239

6 further baseline measures are reported on the registry.

08

Study locations

45 sites
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • PC dba West Cancer Center
    Germantown, Tennessee 38138, United States
  • Krankenhaus der Barmherzigen Brüder
    Vienna, 1020, Austria
  • UZ Gent, Gastro-Enterology
    Ghent, East Flanders 9000, Belgium
  • Trial DIO, UZ Gasthuisberg
    Leuven, Flemish Brabant 3000, Belgium
  • Cliniques universitaires Saint-Luc
    Brussels, 1200, Belgium
  • ICM- VAL d 'Aurelle
    Montpellier, Cedex 5 34298, France
  • Hôpital Morvan CHRU de Brest Institut de cancérologie et d'hematologie
    Brest, 29200, France
  • AP-HM CHU Timone
    Marseille, 13005, France
  • Hôpital Cochin Gastroenterology
    Paris, 75014, France
  • Hôpital Europeen Georges Pompidou
    Paris, 75015, France
  • Hôpital Saint Antoine
    Paris, 75571, France
  • HOPITAL HAUT-LEVEQUE, Av de MAGELLAN
    Pessac, 33604, France
  • ICO- Site René Gauducheau
    Saint-Herblain, 44805, France
  • CHU TOULOUSE Rangueil
    Toulouse, France
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Foggia 71013, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori
    Meldola, Forlì-Cesena 47014, Italy
  • Fondazione del Piemonte per l'Oncologia IRCC Candiolo
    Candiolo, 10060, Italy
  • Ospedale Policlinic San Martin
    Genova, 16132, Italy
  • Ospedale S.M. Misericordia
    Perugia, 06129, Italy
  • Pierre Fabre Investigative Site
    Nagoya, Aichi-ken 464-8681, Japan
  • Pierre Fabre Investigative Site
    Kashiwa, Chiba 277-8577, Japan
  • Pierre Fabre Investigative Site
    Fukuoka, Fukuoka 811-1395, Japan
  • Pierre Fabre Investigative Site
    Osaka, Osaka 540-0006, Japan
  • Pierre Fabre Investigative Site
    Nagaizumi-cho, Shizuoka 411-8777, Japan
  • Pierre Fabre Investigative Site
    Koto-ku,, Tokyo 135-8550, Japan
  • St Antonius Ziekenhuis
    Utrecht, 3543 AZ, Netherlands
  • Hospital Puerta de Hierro
    Madrid, Madrid 28220, Spain
  • Complejo Hospitalario De Navarra S Oncologia Medica
    Pamplona, Navarre 31008, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic I Provincial de Barcelona
    Barcelona, 08036, Spain
  • Institut Català d'Oncologia (ICO L'Hospitalet)
    Barcelona, 08908, Spain
  • Hospital de la Santa Creu i Santa Pau
    Barcelona, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28009, Spain
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Hospital Clínico Universitario de
    Valencia, 46010, Spain
  • Hospital Universitario y Politécnico La FE
    Valencia, 46026, Spain
  • Hospital Alvaro Cunqueiro
    Vigo, 36312, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Torbay Hospital, Lowes Bridge
    Torquay, Devon TQ2 7AA, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • St James Hospital
    Leeds, LS9 7TF, United Kingdom
  • GI research team, OHCT, Guy's Hospital
    London, SE1 9RT, United Kingdom
  • GI Research Team, The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, Elez E, Dekervel J, Ross P, Ruiz-Casado A, Graham J, Kato T, Ruffinelli JC, Andre T, Carriere Roussel E, Klauck I, Groc M, Vedovato JC, Tabernero J. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. J Clin Oncol. 2023 May 10;41(14):2628-2637. doi: 10.1200/JCO.22.01693. Epub 2023 Feb 10. PubMed 36763936 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jun 2020, 17 months.

Results were first posted in Aug 2022, 2 years 2 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 17 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Oct 2, 2018
StartActual
Jan 17, 2019
Primary completionActual
Jun 29, 2020
CompletionActual
Apr 27, 2023
Results first posted
Aug 30, 2022
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03693170
Responsible party
Sponsor
First posted
Oct 2, 2018
Start date
Jan 17, 2019
Primary completion
Jun 29, 2020
Completion
Apr 27, 2023
Results posted
Aug 30, 2022
Last update
Jul 16, 2026

Study contacts

Isabelle KLAUCK, MD
study director · Corporate Medical&Patient/Consumer Division, Pierre Fabre Medicament

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Encorafenib · Binimetinib · Cetuximab

Start the discussion